Insulet Corporation (PODD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $10.58B
Last updated: Nov 17, 2026 at 11:06 AM ET
Insulet Corporation (PODD) P/E Ratio & Valuation History
Insulet (PODD) trades at 21.9x trailing earnings and 3.2x sales. Its P/E of 21.9x is below its 5-year median of 79.1x. Its forward P/E is 19.8x. The median P/E across 9 similar companies is 23.8x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 10.6% higher over the next year. Its free cash flow yield is 2.4%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 21.9x |
| Forward P/E | 19.8x |
| Price to sales | 3.2x |
| Price to book | 6.4x |
| EV/EBITDA | 15.0x |
| Price to FCF | 41.8x |
| EV/FCF | 43.3x |
| PEG | 1.2 |
| FCF yield | 2.4% |
Historical Medians
Against its 10-year medians, its P/S is 67.3% below 9.8x and its P/B is 77.9% below 28.9x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 21.9x | 79.1x | N/A |
| P/S | 3.2x | 8.9x | 9.8x |
| P/B | 6.4x | 16.6x | 28.9x |
Valuation History
Over the 7 of the 10 year ends shown that have a P/E, its P/E ranged from 57.1x in 2025 to 798.8x in 2020. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $284.24 | 57.1x | 7.4x | 13.3x |
| 2024 | $261.07 | 78.4x | 9.0x | 16.0x |
| 2023 | $216.98 | 79.8x | 8.9x | 20.7x |
| 2022 | $294.39 | 303.5x | 15.7x | 43.3x |
| 2021 | $266.07 | 345.5x | 16.5x | 33.4x |
| 2020 | $255.63 | 798.8x | 18.3x | 27.9x |
| 2019 | $171.20 | 611.4x | 14.2x | 144.1x |
| 2018 | $79.32 | N/A | 8.4x | 22.8x |
| 2017 | $69.00 | N/A | 8.6x | 25.3x |
| 2016 | $37.68 | N/A | 5.9x | 34.3x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PODD
What is PODD's forward P/E ratio?
Insulet has a forward P/E ratio of 19.8x.
Is PODD stock overvalued?
GNG's valuation label for PODD is Undervalued. Its P/E of 21.9x compares with a median of 23.8x across 9 similar companies.
What is PODD's price to sales ratio?
Insulet has a price to sales ratio of 3.2x.
What is Insulet's average P/E ratio over 5 years?
Insulet's median P/E over the last 5 years is 79.1x, from 60 month-end values through Oct 2026.
What is PODD's PEG ratio?
Insulet has a PEG ratio of 1.2.
PODD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors